Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. DKSH Holding AG
  6. News
  7. Summary
    DKSH   CH0126673539

DKSH HOLDING AG

(DKSH)
  Report
Delayed Swiss Exchange  -  11:31 2022-10-06 am EDT
71.65 CHF   -1.31%
10/04DKSH's Sustainability Achievements Awarded With the EcoVadis Gold Rating
EQ
10/03Dksh : Provides Patients in Cambodia with High-Quality Medicine Through Exclusive Partnership with PPM
PU
09/29DKSH's Healthcare Unit Partners With Leo Pharma to Deliver Therapeutic Products in Asia
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

DKSH : and pharma& Enter Exclusive Partnership to Build Asian Footprint for Pegasys®

07/20/2022 | 01:14am EDT

Media release

DKSH and pharma& Enter Exclusive Partnership to Build Asian Footprint for Pegasys®

The new collaboration will introduce the specialty care product of pharma& (zr pharma& GmbH) into Hong Kong and Macau markets, while expanding DKSH Business Unit Healthcare's portfolio of high-quality brands.

Hong Kong, July 20, 2022 - DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, and pharma& (zr pharma& GmbH), an Austrian pharmaceutical multinational, have jointly announced their exclusive partnership.

DKSH will provide distribution, marketing and sales services as well as regulatory services to pharma& for their newly acquired specialty care product in Hong Kong, called Pegasys®. Special emphasis will be placed on expanding its channel network. The agreement covers both Hong Kong and Macau.

Pegasys® (Peginterferon alfa 2a) is used to treat patients suffering from Chronic Hepatitis B (CHB) and Chronic Hepatitis C (CHC). The medicine can be administered as a monotherapy or in combination with other medicinal products.

Mr. Kaustav Chatterjee, Commercial Operations Director, pharma&, said: "pharma& is committed to the well-being of our niche patient populations globally and to ensuring that Pegasys® continues to be

provided to those in need. We are excited to partner with DKSH Hong Kong for Pegasys®, as we believe that they have the knowledge and the experience to serve these patient populations and the healthcare professionals who have known and trusted Pegasys® for many years."

Wai Ting Fong, Head of Management and Vice President, Healthcare, DKSH Hong Kong, equally welcomed the partnership: "We are delighted to partner with pharma& to bring niche and original productsto patients in Hong Kong and Macau. With our in-depthexperience and our broad network of healthcare professionals in these two markets, we are confident to effectively support pharma&'s expansion withinand beyond Asia."

About zr pharma& GmbH

pharma& is a privately owned company, aiming at satisfying needs for niche, original, Specialty Care products. Its commitment to patient access for well-established original Specialty Care medicines and its worldwide presence of own subsidiaries, affiliated companies and partnerships, secure sustainable product availability in markets around the world. www.pharmaand.com

About DKSH

DKSH's purpose is to enrich people's lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 33,100 specialists, generating net sales of CHF 11.1 billion in 2021. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical

devices. With around 7,290 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2021. www.dksh.com/hec

1

For further information, please contact:

DKSH Business Unit Healthcare

DKSH Hong Kong

Sheena Flannery

Astrid Lo

Director, Group Communications

Manager, Marketing & Communications

Phone +66 2 220 9739

Phone +852 2895 9610

sheena.flannery@dksh.com

astrid.lo@dksh.com

2

Disclaimer

DKSH Holding AG published this content on 20 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2022 05:13:04 UTC.


© Publicnow 2022
All news about DKSH HOLDING AG
10/04DKSH's Sustainability Achievements Awarded With the EcoVadis Gold Rating
EQ
10/03Dksh : Provides Patients in Cambodia with High-Quality Medicine Through Exclusive Partners..
PU
09/29DKSH's Healthcare Unit Partners With Leo Pharma to Deliver Therapeutic Products in Asia
MT
09/29LEO Pharma and DKSH Partners to Deliver Products and Solutions to People in Asia with S..
CI
09/22Global markets live: Veolia, Meta, Amazon, Salesforce, Target...
MS
09/22Switzerland's DKSH to Buy North American Chemicals Distributor Terra Firma in $360 Mill..
MT
09/22DKSH Performance Materials Strengthens its North American Presence With the Acquisition..
EQ
09/22DKSH Holding AG agreed to acquire Terra Firma.
CI
09/18Dksh : Opens Five new Innovation Centers in China for the Specialty Chemicals and Personal..
PU
09/14Dksh : Joins Global Efforts to Keep Malaysia's Beaches Clean
PU
More news
Analyst Recommendations on DKSH HOLDING AG
More recommendations
Financials
Sales 2022 11 503 M 11 642 M 11 642 M
Net income 2022 219 M 222 M 222 M
Net cash 2022 181 M 184 M 184 M
P/E ratio 2022 21,6x
Yield 2022 2,97%
Capitalization 4 655 M 4 711 M 4 711 M
EV / Sales 2022 0,39x
EV / Sales 2023 0,36x
Nbr of Employees 31 160
Free-Float 49,3%
Chart DKSH HOLDING AG
Duration : Period :
DKSH Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DKSH HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 71,65 CHF
Average target price 86,25 CHF
Spread / Average Target 20,4%
EPS Revisions
Managers and Directors
Stefan P. Butz Chief Executive Officer
Ido Wallach Chief Financial Officer
Marco Gadola Chairman
Sam Oh Chief Information Officer
Laurent Sigismondi Secretary, General Counsel & Head-Governance
Sector and Competitors
1st jan.Capi. (M$)
DKSH HOLDING AG-3.59%4 786
CINTAS CORPORATION-7.05%41 825
TELEPERFORMANCE SE-31.86%15 556
EDENRED SE19.62%11 924
BUREAU VERITAS SA-17.27%10 762
GENPACT LIMITED-13.43%8 464